Striking the target in Wnt-y conditions: Intervening in Wnt signaling during cancer progression

Tura C. Camilli, Ashani T. Weeraratna

Research output: Contribution to journalReview article

Abstract

Wnt signaling can be divided into three pathways, namely the canonical Wnt/β-catenin pathway, and the non-canonical (or heretical) Wnt/Ca2+ and planar cell polarity (PCP) pathways. Although the canonical Wnt/β-catenin pathway is the best described in cancer, increasing data points to the importance of the heretical Wnt pathways in several aspects of tumor progression. The recent advances in understanding the players and mechanisms by which these Wnt pathways contribute to cancer progression have led to the identification of numerous molecules that are already, or could be considered, targets for cancer therapy.

Original languageEnglish (US)
Pages (from-to)702-711
Number of pages10
JournalBiochemical Pharmacology
Volume80
Issue number5
DOIs
StatePublished - Sep 1 2010
Externally publishedYes

Fingerprint

Catenins
Wnt Signaling Pathway
Tumors
Neoplasms
Cell Polarity
Molecules
Therapeutics

Keywords

  • β-Catenin
  • Calcium
  • Cancer
  • PCP
  • Wnt
  • Wnt5A

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Striking the target in Wnt-y conditions : Intervening in Wnt signaling during cancer progression. / Camilli, Tura C.; Weeraratna, Ashani T.

In: Biochemical Pharmacology, Vol. 80, No. 5, 01.09.2010, p. 702-711.

Research output: Contribution to journalReview article

@article{6c386d45df0642b5bc923220f5ac2987,
title = "Striking the target in Wnt-y conditions: Intervening in Wnt signaling during cancer progression",
abstract = "Wnt signaling can be divided into three pathways, namely the canonical Wnt/β-catenin pathway, and the non-canonical (or heretical) Wnt/Ca2+ and planar cell polarity (PCP) pathways. Although the canonical Wnt/β-catenin pathway is the best described in cancer, increasing data points to the importance of the heretical Wnt pathways in several aspects of tumor progression. The recent advances in understanding the players and mechanisms by which these Wnt pathways contribute to cancer progression have led to the identification of numerous molecules that are already, or could be considered, targets for cancer therapy.",
keywords = "β-Catenin, Calcium, Cancer, PCP, Wnt, Wnt5A",
author = "Camilli, {Tura C.} and Weeraratna, {Ashani T.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.bcp.2010.03.002",
language = "English (US)",
volume = "80",
pages = "702--711",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Striking the target in Wnt-y conditions

T2 - Intervening in Wnt signaling during cancer progression

AU - Camilli, Tura C.

AU - Weeraratna, Ashani T.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Wnt signaling can be divided into three pathways, namely the canonical Wnt/β-catenin pathway, and the non-canonical (or heretical) Wnt/Ca2+ and planar cell polarity (PCP) pathways. Although the canonical Wnt/β-catenin pathway is the best described in cancer, increasing data points to the importance of the heretical Wnt pathways in several aspects of tumor progression. The recent advances in understanding the players and mechanisms by which these Wnt pathways contribute to cancer progression have led to the identification of numerous molecules that are already, or could be considered, targets for cancer therapy.

AB - Wnt signaling can be divided into three pathways, namely the canonical Wnt/β-catenin pathway, and the non-canonical (or heretical) Wnt/Ca2+ and planar cell polarity (PCP) pathways. Although the canonical Wnt/β-catenin pathway is the best described in cancer, increasing data points to the importance of the heretical Wnt pathways in several aspects of tumor progression. The recent advances in understanding the players and mechanisms by which these Wnt pathways contribute to cancer progression have led to the identification of numerous molecules that are already, or could be considered, targets for cancer therapy.

KW - β-Catenin

KW - Calcium

KW - Cancer

KW - PCP

KW - Wnt

KW - Wnt5A

UR - http://www.scopus.com/inward/record.url?scp=77954214841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954214841&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2010.03.002

DO - 10.1016/j.bcp.2010.03.002

M3 - Review article

C2 - 20211149

AN - SCOPUS:77954214841

VL - 80

SP - 702

EP - 711

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 5

ER -